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Abstract Rationale: Exaggerated acoustic startle is a
prominent symptom of post-traumatic stress disorder
(PTSD); however, its physiological basis is not well
understood, and there are few available treatments.
Neurobiological research has suggested that anti-kindling
agents and/or glutamate antagonists can attenuate the
acoustic startle response (ASR) in animal models. The
anticonvulsant topiramate is an AMPA antagonist that
also demonstrates potent anti-kindling effects and may,
therefore, have promise in treating trauma-enhanced
ASR. Objective: To evaluate the ability of topiramate to
attenuate stress-induced increases in ASR in a previously
validated animal model of PTSD. Methods: Male Spra-
gue-Dawley rats (n=36) served as controls or received
single prolonged stress (SPS). SPS consisted of 2 h
restraint, forced swim and ether anesthesia, then a 7-day
“undisturbed” period. Animals then received vehicle,
10 mg/kg or 30 mg/kg of topiramate orally, twice daily
for 7 days. ASR was assessed for all animals before and
after the study, in light and dark environments. Re-
sults: SPS produced a sustained increase in the ASR in
both environments, an effect that was significantly
reduced by topiramate. Meanwhile the ASR of control
animals remained unaffected by topiramate. Conclu-
sions: The current results provide one of the few
demonstrations of a single stress episode producing
sustained enhancement of ASR. In addition, topiramate
demonstrates promise in treating exaggerated acoustic
startle symptoms in PTSD or other stress-related disor-
ders.
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Introduction
Exaggerated acoustic startle is a highly prevalent behav-
ioral symptom of post-traumatic stress disorder (PTSD)
(Shalev et al. 1992; Orr et al. 1995). However, the
physiological relationship between traumatic stress and
the acoustic startle response (ASR) remains poorly
understood and there are few available treatments. It has
been suggested that the amygdala, a limbic region with an
established role in mediating the fear response, becomes
kindled or sensitized following exposure to traumatic
events (Liberzon et al. 1999b; Rauch et al. 2000), and
long-term amygdala kindling does produce a significant
increase in ASR in rodent models (Mnard et al. 2002). In
concert, in animal models of ASR, blockade of the
excitatory amino acid glutamate, using AMPA antago-
nists, attenuates fear-potentiated acoustic startle when
injected into the central nucleus of the amygdala and
light-potentiated acoustic startle (LPAS) when adminis-
tered into the bed nucleus of the stria terminalis (Walker
and Davis 1997). When administered into the basolateral
amygdala, it attenuates both phenomena (Walker and
Davis 1997). Thus, compounds demonstrating glutamate
antagonism and/or anti-kindling effects may offer pro-
mise in attenuating exaggerated startle symptoms.
In this regard, the anticonvulsant topiramate demon-
strates potent anti-kindling properties in rodent models
(Wauquier and Zhou 1996) and produces a variety of
inhibitory pharmacological and physiological effects
relevant to ASR, including AMPA antagonism (Gibbs et
al. 2000), GABAA stimulation (White et al. 2000) and
blockade of voltage-gated Na+ channels (Taverna et al.
1999). Although topiramate has shown initial promise in
attenuating some PTSD symptoms, such as flashbacks
and negative thought intrusions (Berlant and van Kam-
men 2002), its effectiveness in attenuating trauma-
enhanced ASR has yet to be tested.
Recently, a rat model of single prolonged stress (SPS)
was developed which successfully reproduced neuroen-
docrine characteristics of PTSD, including enhanced HPA
negative feedback (Liberzon et al. 1997). Preliminary
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data in our laboratory also suggested it produced an
exaggerated ASR under certain conditions such as in the
LPAS paradigm. LPAS assesses the ASR in an uncon-
ditioned aversive environment (bright lights) which is
relevant to humans in that hyperarousal symptoms appear
particularly sensitive in stressful environmental contexts
(Grillon and Amelie 1998). Similarly in animal studies,
ASR is reliably enhanced in brightly lit environments as
compared to dark environments (Walker and Davis 2002).
The purpose of the current study was thus to validate the
ability of SPS to influence ASR in the LPAS paradigm,




Male Sprague-Dawley rats (n=36) (obtained from Charles River)
weighing 150 g at arrival, were housed in groups of three (with ad
libitum food and water) at the VA Ann Arbor animal facility.
Animals were acclimated to colony rooms for 7 days and then
handled for 6 days prior to behavioral testing. During the 6 days of
handling, animals were habituated daily to sweetened condensed
milk (Eagle Brand) administered orally via a 1 ml syringe. The milk
later served as the vehicle for oral administration of topiramate.
Procedure
The experiment was conducted using a 23 design, with two
groups: single prolonged stress (SPS) and control, in one of three
treatment conditions: vehicle-treated, topiramate low dose (10 mg/
kg) and topiramate high dose (30 mg/kg) (n=6/group). Pretreatment
ASR data was collected for all animals, after which one-half
underwent SPS (see below). Following SPS, both control and SPS
animals received two daily administrations of topiramate or vehicle
over 7 days. ASR data was then collected for all animals at least
24 h after the last drug administration (see Table 1).
Acoustic startle response
On the test day, animals were placed in a sound-proof chamber
(373949 cm), containing an electro-voltage platform, connected
to a piezoelectric accelerometer (San Diego Instruments). After
5 min of accommodation, startle stimuli was delivered every 30 s
for 15 min, consisting of a 50 ms burst of 98 dB or 108 dB white
noise. Background noise was set at 55 dB. All animals were tested
in both light and dark environments (counterbalanced) with a 5 min
break in between. Voltage data was filtered, converted, sampled
and transferred to a PC computer using an automated hardware/
software package (San Diego Instruments).
Single prolonged stress (SPS)
Rats were restrained for 2 h, followed immediately by a 20-min
forced swim in 24C water. Forced swim occurred with six rats at a
time in an 18 gallon plastic tub (55.6 cm diameter, 45.4 cm H),
filled two-thirds from the bottom. Following 15 min recuperation,
animals were exposed to ether until the loss of consciousness, and
then left undisturbed in their home cage for 7 days. The undisturbed
period is necessary to replicate conditions that produced PTSD-type
symptoms in previous studies. Prior research demonstrated that
SPS-induced neuroendocrine effects, such as enhanced HPA
negative feedback and changes in the expression of glucocorticoid
receptor mRNA, were only evident if a 7-day undisturbed period
followed SPS (Liberzon et al. 1997, 1999a).
Drug
Vehicle, 10 or 30 mg/kg doses of topiramate (Johnson & Johnson:
Pharmaceutical R & D; Raritan, N.J., USA) were administered
twice daily (at approximately 9:00 a.m. and 5:00 p.m.) for 7 days.
The drug was mixed in sweetened condensed milk (Eagle Brand,
pH 6.3) and 10% 0.1 M KOH solution and administered orally
through a 1 ml syringe. Prior research established that orally
administered topiramate in male rats has a half-life of 2.5 h
(Johnson & Johnson Research Institute: topiramate data sheet), thus
necessitating a twice-daily dosing regimen. Prior research has also
estimated that, on a relative scale, 7 days in the life span of a rat is
roughly equivalent to 6 months in the human life span (Adamec
1997). Thus 7 days of drug administration was believed to reflect
the dosing regimen for chronic drug treatment in human popula-
tions. Following the final drug administration, at least 8 half-lives
elapsed before startle responses were assessed, making it highly
unlikely that the acute effects of topiramate were still influencing
behavioral measures.
Statistics
A repeated measures ANOVA was used to analyze the effects and
interactions of Time (Pre versus Post test), Light (Dark versus
Light), Group (control versus SPS), Sound (98 dB versus 108 dB)
and Drug (vehicle, 10 mg/kg or 30 mg/kg topiramate) on mean
startle amplitude. Where applicable Bonferroni post-hoc analysis
(adjusting for multiple comparisons) was conducted for individual
comparisons.
Results
As indicated in the introduction, it was expected that all
animals would show a higher acoustic startle response
(ASR) in the light condition compared to the dark.
Furthermore, it was expected that this light potentiation
would be enhanced in animals that underwent SPS. A
main effect of Light was observed for all animals in
response to both the 98 dB [F(1,30)=5.017, P<0.05] and
the 108 dB sound burst [F(1,30)=12.019, P<0.01] show-
ing that, indeed, the ASR was higher in the light
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environment. However, this potentiation did not differ-
entially effect the SPS group more than the controls as
there was no LightGroup interaction at either sound
level [98 dB: F(1,34)=1.119, P=0.282; 108 dB:
F(1,34)=1.237, P=0.274].
In the current study, two pulse intensities, 98 dB and
108 dB, were used in the LPAS paradigm. However, the
lower pulse intensity appeared to produce a very modest
ASR. Thus, the mean startle amplitude in response to
98dB (10.5€0.64) was less than 25% of that produced at
108 dB (45.2€2.4). Even though light did potentiate ASR
in response to both sound levels, at 98 dB this potentiation
was minimal (dark: 9.8€.83, light: 11.4€0.97) in compar-
ison to 108 dB (dark: 39.57€2.76, light: 51.02€3.87; see
Fig. 1). Furthermore, 98 dB was ineffective in eliciting
significant changes in ASR in animals exposed to SPS
[F(1,5)=0.600 P=0.474) (see Fig. 1). Indeed, a significant
SoundTimeGroup interaction [F(1,30)=9.114, P<0.01]
revealed the effect of SPS on the ASR was at the 108 dB
sound only. Therefore, further analysis of the effect of
topiramate on SPS-enhanced ASR could only be assessed
in the 108 dB condition.
With regards to the 108 dB sound burst, subsequent
analysis assessed the effects of Time and Group on ASR.
Thus, in animals that received vehicle only, a significant
TimeGroup interaction was observed [F(1,10)=14.49,
P<0.01]. Bonferonni post-hoc analysis revealed that
animals exposed to SPS had a significantly higher ASR
post-SPS (time 2) compared to pre-SPS (time 1) (P<0.01).
Furthermore, at time 2, SPS-exposed animals had a
significantly higher ASR than control animals (P<0.05)
(see Fig. 2). The effect of SPS on startle was evident in
both the dark [TimeGroup: F(1,10)=12.68, P<0.01] and
light environments [F(1,10)=5.54, P<0.01].
In response to 108 dB, analysis also examined the
effect of topiramate on the ASR of SPS and control
animals, at the second time point (day 17). In this case, a
Fig. 1 Comparison of the effects of light (left panel) and SPS (right
panel) on mean startle amplitude in response to 98 dB or 108 dB
sound bursts. The left panel shows the effect of light on all groups,
whereas the right panel shows the effect of SPS on vehicle-treated
animals
Fig. 2 Mean startle amplitude, in response to 108 dB, for control
and SPS rats at time 1 (day 1) and time 2 (day 17). SPS-exposed
rats show a heightened startle response at time 2, whereas for
control animals the startle response remains unchanged or slightly
decreased over time. *Indicates significantly higher startle response
compared to SPS (time 1) (P<0.01). #Indicates significantly higher
startle response compared to control (time 2) (P<0.05)
Fig. 3 Mean startle amplitude for control and SPS rats, in response
to 108 dB, following chronic treatment with vehicle, low (10 mg/
kg) or high (30 mg/kg) topiramate, twice daily. *Indicates
significantly different startle amplitude between topiramate and
vehicle-treated SPS animals (P<0.01)
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two-way ANOVA revealed a significant GroupDrug
interaction [F(2,30)=4.835, P<0.05] (see Fig. 3). Bonfer-
roni post-hoc analysis further revealed that, in animals
exposed to SPS, a significantly lower ASR was observed
for topiramate-treated animals (10 mg/kg and 30 mg/kg)
as compared to vehicle-treated animals (P<0.01). The
effect of topiramate on ASR was observed in both the
dark [GroupDrug: F(2,30)=3.441, P<0.05] and light
environments [F(2,29)=3.436, P<0.05].
Discussion
The current study demonstrates that SPS produces a
sustained exaggeration of the ASR. In addition, chronic
treatment with topiramate, following SPS, eliminated this
exaggeration. This reduction in ASR occurred at both
doses, and in both the light and dark environment.
Topiramate produced no noticeable effects on startle
response in control rats. To our knowledge, this represents
the first demonstration of an anti-convulsant agent
successfully attenuating stress-induced exaggerations of
ASR, without affecting the ASR of non-stressed controls.
Ebert and Koch (1996) had found that carbamazepine
could reduce the ASR in control and partially kindled rats,
although it had a limited effect in fully kindled rats.
Research with other established anticonvulsants, such as
phenytoin or valproic acid have been limited with respect
to ASR.
At this point, the precise mechanism behind the effect
of topiramate on stress-induced enhancement of ASR is
unknown. Since kindling has been linked to ASR
potentiation in certain conditions (Mnard et al. 2002),
the anti-kindling and/or anticonvulsant properties of
topiramate may be involved. Its effects as an AMPA
antagonist might also be relevant. Walker and Davis
(1997) showed that AMPA antagonists infused into the
bed nucleus of stria terminalis (BNST) blocked light-
potentiated ASR, though not fear-potentiated startle.
Infusions into the basolateral amygdala disrupted both
phenomena. Topiramate may also act at the locus
coeruleus (LC), which has a well-established role in
mediating arousal. Forced swim sensitizes the electrical
discharge activity of LC neurons in response to local CRH
administration (Curtis et al. 1999), suggesting such
stressors may lower the threshold of activation. Sensory
input to the LC is modulated to a considerable degree by
glutamate and GABA neurotransmission (Aston-Jones et
al. 1990), both of which are targets of topiramate activity.
Future studies would benefit by elucidating the precise
mechanisms mediating the effects of topiramate on ASR
and by further characterizing the full range of therapeutic
doses. For instance, additional experiments may seek to
independently target specific pharmacological effects of
topiramate (e.g. AMPA antagonism, GABAA stimulation)
and/or attempt to identify the threshold dose or minimum
dosing regimen at which topiramate begins to demon-
strate its startle-reducing effects.
A second intention of the current study was to validate
further the ability of the SPS paradigm to produce
exaggerations in ASR. In this regard, the current results
provide one of the few demonstrations of a single stress
episode producing long-term ASR increases. Single
episodes of inescapable tailshock also produced exagger-
ated ASR, though this exaggeration appeared and disap-
peared at 7 days post-stress (Servatius et al. 1995).
Similarly, predator exposure, involving single 5-min non-
injurious cat exposure, produced an exaggerated ASR in
rats 8 days post-stress (Adamec 1993). In addition to
behavioral effects, SPS was previously shown to repro-
duce PTSD-related neuroendocrine changes, including an
upregulation in glucocorticoid receptor mRNA in the
hippocampus and enhanced glucocorticoid negative feed-
back (Liberzon et al. 1997, 1999a). Kato et al. (2002)
further demonstrated SPS-induced increases in low-
frequency stimulated long-term depressions (LTD) in
hippocampal neurons. The physiological converse, inhi-
bition of long-term potentiation (LTP), reliably occurs in
hippocampal neurons following a number of stressors
including restraint, inescapable tail-shock (Shors et al.
1989, 1994; Kim et al. 1996) and predator exposure
(Mesches et al. 1999). Taken together, SPS may thus
prove a highly valid animal model of PTSD, capable of
reproducing behavioural, neuroendocrine and neurophys-
iological symptoms.
The current results therefore demonstrate that SPS is
capable of producing a sustained enhancement of the
ASR, which is attenuated by chronic treatment with
topiramate. At this point, a number of potential mecha-
nisms are possible for the startle-reducing effects of
topiramate, although further investigation is required. The
SPS model may be of significant value in delineating the
neurobiological basis of trauma-enhanced ASR, and
topiramate itself appears to show considerable promise
in treating exaggerated startle symptoms in PTSD and
other stress-related disorders.
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